BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 31

• Pharm Country

  Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D

  Inventiva will hold an investor conference on Tuesday, March 19, to share the results of the LEGEND Phase II trial, a placebo-controlled, study evaluating lanifibranor alone and in combination with the SGLT2 inhibitor empagliflozin in patients with MASH/NASH and type 2 diabetes.

  March 13, 2024

   · 

  11 min read
• Business

  Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024

  Mineralys Therapeutics, Inc. (NASDAQ: MLYS) today announced it will report its financial results from the fourth quarter and full year ended December 31, 2023, before the financial markets open on Thursday, March 21, 2024.

  March 13, 2024

   · 

  1 min read
• Genetown

  PepGen to Participate in Upcoming Investor Conferences - March 13, 2024

  PepGen Inc. announced that management will participate in the following upcoming investor conferences.

  March 13, 2024

   · 

  1 min read
• Business

  Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024

  Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that the company will host a conference call and webcast on March 19, 2024 at 4:30 pm ET to provide a business update and report fourth quarter and full year 2023 financial results.

  March 13, 2024

   · 

  1 min read
• Business

  electroCore Announces Fourth Quarter and Full Year 2023 Financial Results

  electroCore, Inc. (Nasdaq: ECOR) (the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced fourth quarter and full year 2023 financial results.

  March 13, 2024

   · 

  10 min read